CA2578670C - Neural proteins as biomarkers for nervous system injury and other neural disorders - Google Patents

Neural proteins as biomarkers for nervous system injury and other neural disorders Download PDF

Info

Publication number
CA2578670C
CA2578670C CA2578670A CA2578670A CA2578670C CA 2578670 C CA2578670 C CA 2578670C CA 2578670 A CA2578670 A CA 2578670A CA 2578670 A CA2578670 A CA 2578670A CA 2578670 C CA2578670 C CA 2578670C
Authority
CA
Canada
Prior art keywords
protein
biomarkers
neural
injury
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2578670A
Other languages
English (en)
French (fr)
Other versions
CA2578670A1 (en
Inventor
Ronald Hayes
Ka-Wang Kevin Wang
Ming-Chen Liu
Monika Oli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Banyan Biomarkers Inc
University of Florida Research Foundation Inc
Original Assignee
Banyan Biomarkers Inc
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyan Biomarkers Inc, University of Florida Research Foundation Inc filed Critical Banyan Biomarkers Inc
Priority to CA2955027A priority Critical patent/CA2955027A1/en
Publication of CA2578670A1 publication Critical patent/CA2578670A1/en
Application granted granted Critical
Publication of CA2578670C publication Critical patent/CA2578670C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2578670A 2004-04-15 2005-04-15 Neural proteins as biomarkers for nervous system injury and other neural disorders Expired - Lifetime CA2578670C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2955027A CA2955027A1 (en) 2004-04-15 2005-04-15 Neural proteins as biomarkers for nervous system injury and other neural disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56294404P 2004-04-15 2004-04-15
US60/562,944 2004-04-15
PCT/US2005/012746 WO2005106038A2 (en) 2004-04-15 2005-04-15 Neural proteins as biomarkers for nervous system injury and other neural disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2955027A Division CA2955027A1 (en) 2004-04-15 2005-04-15 Neural proteins as biomarkers for nervous system injury and other neural disorders

Publications (2)

Publication Number Publication Date
CA2578670A1 CA2578670A1 (en) 2005-11-10
CA2578670C true CA2578670C (en) 2017-03-07

Family

ID=35242271

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2955027A Abandoned CA2955027A1 (en) 2004-04-15 2005-04-15 Neural proteins as biomarkers for nervous system injury and other neural disorders
CA2578670A Expired - Lifetime CA2578670C (en) 2004-04-15 2005-04-15 Neural proteins as biomarkers for nervous system injury and other neural disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2955027A Abandoned CA2955027A1 (en) 2004-04-15 2005-04-15 Neural proteins as biomarkers for nervous system injury and other neural disorders

Country Status (7)

Country Link
US (2) US7396654B2 (enExample)
EP (2) EP2207033B1 (enExample)
JP (1) JP4659025B2 (enExample)
AU (1) AU2005238446B2 (enExample)
CA (2) CA2955027A1 (enExample)
ES (1) ES2482142T3 (enExample)
WO (1) WO2005106038A2 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
CA2555373C (en) 2004-02-06 2014-04-29 Wake Forest University Health Sciences Tissue evaluation using global tissue characteristics of non-invasive imaging and systems for determining global tissue characteristics of images
US7747308B2 (en) * 2004-02-06 2010-06-29 Wake Forest University Health Sciences Non-invasive systems and methods for the determination of cardiac injury using a characterizing portion of a voxel histogram
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2367311T3 (es) * 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
WO2006012351A2 (en) * 2004-06-25 2006-02-02 Washington University Markers for brain damage
AU2006232370B2 (en) * 2005-04-01 2011-10-06 Banyan Biomarkers Biomakers of liver injury
US8048638B2 (en) 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
WO2007092159A2 (en) 2006-02-02 2007-08-16 Wake Forest University Health Sciences Cardiac visualization systems for displaying 3-d images of cardiac voxel intensity distributions with optional physician interactive boundary tracing tools
EP1815863A1 (en) * 2006-02-03 2007-08-08 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of TLR3 agonists for the treatment of neurodegenerative disorders
EP1840574A1 (en) * 2006-03-30 2007-10-03 Institut Pasteur Use of the alpha chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases
ES2407975T3 (es) 2006-05-09 2013-06-17 The University Of British Columbia Marcadores proteínicos de la artritis disueltos
WO2007136617A2 (en) * 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
DE102006033294A1 (de) * 2006-07-17 2008-01-31 Evotec Technologies Gmbh Analyseverfahren für chemische und/oder biologische Proben
WO2008097618A1 (en) * 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
WO2008124096A1 (en) * 2007-04-04 2008-10-16 Gaia Medical Institute Systems and methods for analyzing persistent homeostatic perturbations
JP2009052933A (ja) * 2007-08-24 2009-03-12 Rakuno Gakuen プリオン病の検出方法及び診断キット
BRPI0819063A2 (pt) 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
WO2009094713A1 (en) * 2008-01-29 2009-08-06 Murdoch Childrens Research Institute Diagnosis and treatment of sensory defect
AU2009212463A1 (en) * 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
AU2009282117B2 (en) * 2008-08-11 2016-05-12 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
RU2381505C1 (ru) * 2008-09-30 2010-02-10 Федеральное Государственное Учреждение "Государственный Научный Центр Дерматовенерологии Федерального Агентства По Высокотехнологичной Медицинской Помощи" Способ диагностики сифилиса с использованием метода прямого протеомного профилирования сыворотки крови
WO2010065878A1 (en) 2008-12-05 2010-06-10 C2N Diagnostics Methods for measuring concentrations of biomolecules
DK2406633T3 (en) 2009-03-11 2019-04-01 Augurex Life Sciences Corp COMPOSITIONS AND PROCEDURES FOR CHARACTERIZING ARTHRITIC CONDITIONS
CA2766057A1 (en) * 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20120202231A1 (en) * 2009-07-18 2012-08-09 Kevin Ka-Wang Wang Synergistic biomarker assay of neurological condition using s-100b
JP5909447B2 (ja) 2009-09-14 2016-04-26 バンヤン・バイオマーカーズ・インコーポレーテッド ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
WO2012141674A2 (en) 2010-01-26 2012-10-18 Banyan Biomarkers, Inc. Compositions and methods relating to argininosuccinate synthetase
JP2013524220A (ja) * 2010-04-01 2013-06-17 バンヤン・バイオマーカーズ・インコーポレイテッド 神経毒性を検出するためのマーカーおよびアッセイ
WO2011160096A2 (en) * 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
US9746481B2 (en) 2010-10-14 2017-08-29 The Johns Hopkins University Biomarkers of brain injury
EP2642919A4 (en) * 2010-11-26 2014-10-08 Brigham & Womens Hospital METHOD FOR THE INVESTIGATION OF REPEATED HEAD BREAKDOWN THROUGH TWO-DIMENSIONAL MAGNETIC RESONANCE SPECTROSCOPY
CN103547296B (zh) 2011-03-11 2016-08-17 非营利性组织佛兰芒综合大学生物技术研究所 用于抑制和检测蛋白质的分子和方法
US20140141458A1 (en) 2011-05-12 2014-05-22 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
WO2012170998A1 (en) * 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
US20120322682A1 (en) * 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
KR101333207B1 (ko) * 2011-07-13 2013-11-26 부산대학교 산학협력단 자궁내막증과 연관된 유전자 마커 및 이의 용도
US20130046093A1 (en) * 2011-08-18 2013-02-21 Korea Institute Of Science And Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
WO2013040502A2 (en) * 2011-09-14 2013-03-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder
WO2013056377A1 (en) 2011-10-21 2013-04-25 Augurex Life Sciences Corporation Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013071300A1 (en) * 2011-11-11 2013-05-16 Popinchalk Sam Method to diagnose and characterize lesions in the peripheral nervous system
AU2012345902A1 (en) * 2011-12-02 2014-06-26 C2N Diagnostics Methods for measuring concentrations of biomolecules
EP2823063A4 (en) * 2012-03-05 2016-02-10 Berg Llc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DEVELOPMENT INVASIVE DISORDER
EP2825893A4 (en) 2012-03-13 2016-03-16 Univ Johns Hopkins CITRILLINATED BRAIN AND NERVE PROTEINS AS A BIOMARKER OF BRAIN INJURY OR NERVOUS GENERATION
HK1209161A1 (en) 2012-04-02 2016-03-24 博格有限责任公司 Interrogatory cell-based assays and uses thereof
CN102735834B (zh) * 2012-05-11 2014-09-03 中国兽医药品监察所 一种检测苯乙醇胺a的酶联免疫试剂盒
JP5984559B2 (ja) * 2012-07-31 2016-09-06 オリンパス株式会社 壊死細胞領域検出装置及びその方法、壊死細胞領域検出プログラム
EP2883052B8 (en) 2012-08-10 2019-03-13 Istituto Superiore di Sanità Biomarkers
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
US10082500B2 (en) 2013-08-22 2018-09-25 Franz Baudenbacher Device and method for detecting a target analyte
GB201319492D0 (en) * 2013-11-05 2013-12-18 Secr Defence Biomarkers for traumatic brain injury
JP2017515819A (ja) * 2014-05-08 2017-06-15 サンガモ セラピューティクス， インコーポレイテッド ハンチントン病を処置するための方法および組成物
US20170254818A1 (en) * 2014-08-24 2017-09-07 The Board Of Regents Of The University Of Texas Sy Stem Cns-specific biomarkers for cns diseases or injuries
HK1243509A1 (zh) 2014-09-11 2018-07-13 博格有限责任公司 基於患者数据的用於健康护理诊断和治疗的贝叶斯因果关系网络模型
EP3029466A1 (en) 2014-12-03 2016-06-08 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Methods for differentiating ischemic stroke from hemorrhagic stroke
EP3254106A4 (en) 2015-02-05 2018-10-03 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
US10667737B2 (en) 2015-03-23 2020-06-02 International Business Machines Corporation Monitoring a person for indications of a brain injury
US10244971B2 (en) * 2015-05-12 2019-04-02 International Business Machines Corporation Mouthguard for analysis of biomarkers for traumatic brain injury
EP3452828A4 (en) * 2016-05-06 2019-12-04 Nanosomix Inc. SYNAPTIC PROTEIN BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF MORBUS ALZHEIMER AND OTHER NEURODEGENERATIVE ILLNESSES
EP3452832A4 (en) * 2016-05-06 2020-04-22 Duke University METHODS AND KITS FOR DIAGNOSIS AND TREATMENT OF DISEASES OR INJURIES OF THE NERVOUS SYSTEM
JP2019535015A (ja) * 2016-10-03 2019-12-05 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
RU2648515C1 (ru) * 2016-12-21 2018-03-26 Общество с ограниченной ответственностью "ДРД" Прогнозирование течения и исхода комы и посткоматозных бессознательных состояний (в том числе вегетативных) с помощью гемотестов
WO2018132791A1 (en) * 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes
CA3052513A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
AU2018250688B2 (en) 2017-04-15 2024-07-04 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
AU2018256845B2 (en) 2017-04-28 2024-03-14 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
EP3631465A1 (en) 2017-05-25 2020-04-08 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
AU2018275236B2 (en) 2017-05-30 2024-11-07 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
CN107748263A (zh) * 2017-08-31 2018-03-02 北京臻惠康生物科技有限公司 一种纤维蛋白溶酶原的新用途及试剂盒
CA3067055A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
EP3721233A2 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
US20190383832A1 (en) 2017-12-29 2019-12-19 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
CN108267598A (zh) * 2018-02-06 2018-07-10 河北省健海生物芯片技术有限责任公司 一种用于肺癌筛查的蛋白芯片的制备方法
WO2019169309A1 (en) * 2018-03-02 2019-09-06 Berger Russell Jay Methods, apparatuses and kits for rapid testing of traumatic brain injuries
CN113748343A (zh) * 2019-03-28 2021-12-03 H.隆德贝克有限公司 pS396测定用于诊断TAU蛋白病的用途
US12148604B2 (en) * 2019-04-22 2024-11-19 Amit, Inc. Method for generating data set for training a prediction model and apparatus comprising the prediciton model
BR112022004094A2 (pt) * 2019-09-05 2022-05-31 Octave Bioscience Inc Biomarcadores para predizer atividade de doença de esclerose múltipla
KR102443101B1 (ko) * 2020-12-23 2022-09-13 단국대학교 천안캠퍼스 산학협력단 신경 발달 장애의 발병 위험도 예측용 바이오마커 조성물
US12174186B2 (en) * 2021-03-29 2024-12-24 Euroimmun Medizinische Labordiagnostika Ag Method and reagents for the detection of an autoantibody
CN113584021A (zh) * 2021-06-17 2021-11-02 中国人民解放军军事科学院军事医学研究院 用于微波辐射致神经元突触损伤的靶标lncRNA：MSTRG.31953.1
EP4389126A4 (en) * 2021-08-20 2025-05-14 Dankook University Cheonan Campus Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder
KR102684933B1 (ko) * 2021-08-20 2024-07-16 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도
CN113970643B (zh) * 2021-11-23 2023-06-30 北京大学人民医院 检测抗uch-l1表位的自身抗体的试剂在制备sle血清诊断相关产品中的应用
JP2025541672A (ja) * 2022-11-16 2025-12-23 グリフォン バイオ， インク． 生物流体試料を使用した脳特異的な異常神経症状のためのバイオマーカーパネル
IT202300005046A1 (it) * 2023-03-17 2024-09-17 Fondazione Istituito Neurologico Naz Casimiro Mondino Metodica di individuazione di autoanticorpi diretti contro epitopi conformazionali della proteina proteolipidica (plp) umana nel siero e nel liquor di pazienti con malattie demielinizzanti acquisite
CN116879564A (zh) * 2023-09-06 2023-10-13 暨南大学附属第一医院（广州华侨医院） 基于蛋白质组学及磷酸化蛋白质修饰组学的脊髓损伤生物标志物及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5118606A (en) 1988-09-02 1992-06-02 The Regents Of The University Of California Methods for detecting cellular pathology by assaying spectrin and spectrin breakdown products
US5118937A (en) 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69334274D1 (de) 1992-05-29 2009-05-14 Univ Rockefeller Verfahren zur Bestimmung der Folge von Peptiden unter Verwendung eines Massenspektrometers
US5792664A (en) 1992-05-29 1998-08-11 The Rockefeller University Methods for producing and analyzing biopolymer ladders
ATE242485T1 (de) 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5536639A (en) 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
JP2003070498A (ja) * 2001-07-19 2003-03-11 Pharma Design Inc ユビキチンカルボキシルターミナルヒドロラーゼｌ１遺伝子異常の検出方法
US20030040660A1 (en) * 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
EP2348317B1 (en) * 2002-09-11 2014-12-03 University Of Florida Research Foundation, Inc. Detection of traumatic brain injury using alpha II spectrin break-down products (SBDP)
WO2005004794A2 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
ES2367311T3 (es) * 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
AU2006232370B2 (en) * 2005-04-01 2011-10-06 Banyan Biomarkers Biomakers of liver injury

Also Published As

Publication number Publication date
ES2482142T3 (es) 2014-08-01
CA2578670A1 (en) 2005-11-10
AU2005238446A1 (en) 2005-11-10
US20090087868A1 (en) 2009-04-02
EP1745149A2 (en) 2007-01-24
JP2007532915A (ja) 2007-11-15
JP4659025B2 (ja) 2011-03-30
EP2207033B1 (en) 2014-06-18
WO2005106038A2 (en) 2005-11-10
US20050260654A1 (en) 2005-11-24
WO2005106038A3 (en) 2007-08-02
CA2955027A1 (en) 2005-11-10
AU2005238446B2 (en) 2009-07-30
US7396654B2 (en) 2008-07-08
EP1745149A4 (en) 2008-08-06
EP2207033A2 (en) 2010-07-14
EP2207033A3 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
US11221342B2 (en) Neural proteins as biomarkers for nervous system injury and other neural disorders
CA2578670C (en) Neural proteins as biomarkers for nervous system injury and other neural disorders
US20140303041A1 (en) In vitro diagnostic devices for nervous system injury and other neural disorders
US7456027B2 (en) Proteolytic biomarkers for traumatic injury to the nervous system
US11994522B2 (en) Biomarker detection process and assay of neurological condition
US7611858B1 (en) Detection of cannabinoid receptor biomarkers and uses thereof
US10725054B2 (en) Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
US20110082203A1 (en) Process to diagnose or treat brain injury
WO2011160096A2 (en) Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
HK40083580A (en) Protein markers for assessing alzheimer's disease

Legal Events

Date Code Title Description
EEER Examination request